Literature DB >> 12606841

Attenuated left prefrontal activation during a verbal fluency task in patients with depression.

G Okada1, Y Okamoto, S Morinobu, S Yamawaki, N Yokota.   

Abstract

Functional neuroimaging studies on patients with depression have found abnormal activity in the left prefrontal and anterior cingulate cortex compared with healthy controls. Other studies have shown that these regions become active in healthy subjects during verbal fluency tasks, while patients with depression show impaired performance on such tasks. We used functional magnetic resonance imaging to investigate changes in cerebral blood oxygenation associated with a verbal fluency task in depressed patients and healthy volunteers. In contrast to 10 age- and sex-matched healthy control subjects who activated the left prefrontal cortex and the anterior cingulate cortex during word generation, 10 depressed subjects showed attenuated activation in the left prefrontal cortex and did not show significant activation in the anterior cingulate cortex. These findings suggest that impaired performance during verbal fluency task in depressed patients is associated with abnormal neural responses within these regions. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2003        PMID: 12606841     DOI: 10.1159/000068871

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  36 in total

Review 1.  Frontocingulate dysfunction in depression: toward biomarkers of treatment response.

Authors:  Diego A Pizzagalli
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

Review 2.  Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review.

Authors:  Hannah R Snyder
Journal:  Psychol Bull       Date:  2012-05-28       Impact factor: 17.737

3.  Effect of acute tryptophan depletion on pre-frontal engagement.

Authors:  Paul P Allen; Anthony J Cleare; Francis Lee; Paolo Fusar-Poli; Nigel Tunstall; Cynthia H Y Fu; Micheal J Brammer; Philip K McGuire
Journal:  Psychopharmacology (Berl)       Date:  2006-07-06       Impact factor: 4.530

Review 4.  [Executive functions in patients with depression. The role of prefrontal activation].

Authors:  N Vasic; R C Wolf; H Walter
Journal:  Nervenarzt       Date:  2007-06       Impact factor: 1.214

5.  Primary functional brain connections associated with melancholic major depressive disorder and modulation by antidepressants.

Authors:  Naho Ichikawa; Giuseppe Lisi; Noriaki Yahata; Go Okada; Masahiro Takamura; Ryu-Ichiro Hashimoto; Takashi Yamada; Makiko Yamada; Tetsuya Suhara; Sho Moriguchi; Masaru Mimura; Yujiro Yoshihara; Hidehiko Takahashi; Kiyoto Kasai; Nobumasa Kato; Shigeto Yamawaki; Ben Seymour; Mitsuo Kawato; Jun Morimoto; Yasumasa Okamoto
Journal:  Sci Rep       Date:  2020-02-26       Impact factor: 4.379

Review 6.  Epigenetic and Neural Circuitry Landscape of Psychotherapeutic Interventions.

Authors:  Christopher W T Miller
Journal:  Psychiatry J       Date:  2017-05-25

7.  Increased neural activity during overt and continuous semantic verbal fluency in major depression: mainly a failure to deactivate.

Authors:  Heidelore Backes; Bruno Dietsche; Arne Nagels; Mirjam Stratmann; Carsten Konrad; Tilo Kircher; Axel Krug
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-02-21       Impact factor: 5.270

8.  Brain imaging correlates of cognitive impairment in depression.

Authors:  Emma J Thomas; Rebecca Elliott
Journal:  Front Hum Neurosci       Date:  2009-10-09       Impact factor: 3.169

9.  Response conflict and frontocingulate dysfunction in unmedicated participants with major depression.

Authors:  Avram J Holmes; Diego A Pizzagalli
Journal:  Neuropsychologia       Date:  2008-06-04       Impact factor: 3.139

Review 10.  In search of neural endophenotypes of postpartum psychopathology and disrupted maternal caregiving.

Authors:  E L Moses-Kolko; M S Horner; M L Phillips; A E Hipwell; J E Swain
Journal:  J Neuroendocrinol       Date:  2014-10       Impact factor: 3.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.